{"id":305042,"date":"2026-08-17T00:00:00","date_gmt":"2026-08-17T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0002-2024-biopharma-diabetic-macular-edema-diabetic-retinopathy-landscape-forecast-disease-2\/"},"modified":"2026-09-20T23:09:24","modified_gmt":"2026-09-20T23:09:24","slug":"dlsfop0002-2026-biopharma-diabetic-macular-edema-diabetic-retinopathy-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0002-2026-biopharma-diabetic-macular-edema-diabetic-retinopathy-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Diabetic Macular Edema \/ Diabetic Retinopathy &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p><span>Dia<\/span>betic macular edema (<abbr title=\"diabetic macular edema\">DME<\/abbr>), a complication of diabetic retinopathy (<abbr title=\"diabetic retinopathy\">DR<\/abbr>), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left untreated. The treatment landscape for <abbr title=\"diabetic retinopathy\">DR<\/abbr> and <abbr title=\"diabetic macular edema\">DME<\/abbr> is evolving rapidly, with established anti-<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr> therapies such as Eylea and off-label Avastin remaining central to management. Additionally, the sustained-release corticosteroid implants Ozurdex and Iluvien provide alternative options. Since 2022, the market has seen increased competition with the launch of Vabysmo, Eylea HD \/ Eylea 8 mg, and biosimilars of Eylea. The anticipated approvals of Regenxbio \/ AbbVie\u2019s sura-vec <abbr title=\"suprachoroidal space\">SCS<\/abbr> and 4DMT \/ Otsuka\u2019s 4D-150\u2014two innovative gene therapies\u2014and EyePoint\u2019s Duravyu, Ocular Therapeutix\u2019s Axpaxli, and Ashvattha\u2019s migaldendranib\u2014three novel <abbr title=\"tyrosine kinase inhibitor\">TKI<\/abbr>s\u2014represent a breakthrough in the treatment of retinal diseases and are likely to shift the current treatment paradigm and could transform the treatment of <abbr title=\"diabetic retinopathy\">DR<\/abbr> and <abbr title=\"diabetic macular edema\">DME<\/abbr> patients in the future.\u00a0<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large are the treatable <abbr title=\"diabetic retinopathy\">DR<\/abbr> and <abbr title=\"diabetic macular edema\">DME<\/abbr> populations, and how will diagnosis and drug-treatment rates change over time?<\/li>\n<li>What key differences do <abbr title=\"key opinion leader\">KOL<\/abbr>s perceive between current <abbr title=\"intravitreal\">IVT<\/abbr> therapies? How is the use of these drugs expected to change over the next 10 years?<\/li>\n<li>How will <abbr title=\"diabetic retinopathy\">DR<\/abbr> and <abbr title=\"diabetic macular edema\">DME<\/abbr> treatment algorithms change as innovative products like gene therapies and long-acting <abbr data-abbreviation-entity=\"4974\" title=\"tyrosine kinase inhibitor\">TKI<\/abbr>s launch?<\/li>\n<li>How will market dynamics be impacted by the launch of biosimilars of Eylea?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-305042","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-macular-edema","biopharma-therapy-areas-diabetic-retinopathy","biopharma-therapy-areas-ophthalmology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}